| SUPERNUS PHARMAC.DL -,001 |
| USA |
| Gesundheit |
| US8684591089 / A1JX3U |
| S49 (Frankfurt) / SUPN (NASDAQ) |
| FRA:S49, ETR:S49, S49:GR, NASDAQ:SUPN |
| - |
| https://www.supernus.com/ |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its primary function is to innovate therapeutic solutions that address..
>Volltext.. |
| 2566.03 Mio. EUR |
| 2338.21 Mio. EUR |
| 622.84 Mio. EUR |
| 42.26 Mio. EUR |
| -33.4 Mio. EUR |
| -0.59 EUR |
| 35.5 Mio. EUR |
| 111.28 Mio. EUR |
| 41 Mio. EUR |
| 0.91 |
| -4.25% |
| -146% |
| - |
| - |
| - |
| SUPERNUS |
| 05.04.26 |